A Reckoning for REMS: FDA’s Risk Program in the Spotlight

Tags: neutral

Leave a Reply

Name (required)

Mail (will not be published) (required)

Website

• Subscribe to our feed by e-mail
• Subscribe to our RSS Feed
• Follow Snapshot on Twitter
• Join our network on Linked In
• Friend us on Facebook

• RSHC Twitter Feed

  • Good inforgraphic on B2B content marketing http://t.co/Oasb51qw about 2 hours ago from HootSuite ReplyRetweetFavorite
  • RT @sciam: The Crisis of Antibiotic Resistance http://t.co/4uDdEBt4 about 19 hours ago from web ReplyRetweetFavorite
  • RT @marynmck: FDA: Acid reflux drugs increase risk of C. diff (MedPage Today) - By Todd Neale, Senior Staff Writer,... http://t.co/Dz6DgkAO about 19 hours ago from web ReplyRetweetFavorite
  • Today's News:India drug firms accused of price collusion,Roche CEO interview,CDC delays approved vaccines?http://t.co/GE3ckC25 01:32:06 PM February 08, 2012 from HootSuite ReplyRetweetFavorite
  • RT @genentechnews: #Genentech announced the #FDA has granted priority review for pertuzumab http://t.co/kgyAKwSF 05:07:03 PM February 07, 2012 from web ReplyRetweetFavorite

  @Betsy_RSHC

• Search